Main Article Content
Neurodegenerative disorder, palmitoylethanolamide, hydroxytyrosol, Bacopa monnieri extracts, dietary phytocomponents, food supplementation
Neurological disorders like Parkinson disease and Alzheimer disease, spinal cord injury and stroke have some recurrent characteristics such as abnormal protein aggregation, oxidative stress induction, apoptosis, excitotoxicity, perturbation of intracellular Ca2+ homeostasis and inflammation. To date, there are few effective treatments available and the drugs currently used to manage the symptoms have important side effects. Therefore, research studies are focusing on natural phytochemicals present in diet as bioactive molecules potentially useful against neurodegenerative diseases. In this review, we will discuss the neuroprotective role of palmitoylethanolamide, hydroxytyrosol, and Bacopa monnieri extracts against neuroinflammation and neurodegeneration, thereby revealing their remarkable potential as novel therapeutic options for the treatment of neurodegenerative disorders.
2. Beggiato S, Tomasini MC, Ferraro L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in Alzheimer’s disease. Front Pharmacol 2019; 10: 821.
3. Tsuboi K, Uyama T, Okamoto Y, Ueda N. Endocannabinoids and related N-acylethanolamines: biological activities and metabolism. Inflamm Regen 2018; 38: 28.
4. Scuderi C, Bronzuoli MR, Facchinetti R, et al. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects. Transl Psychiatry 2018; 8: 32.
5. Balvers MG, Verhoeckx KC, Meijerink J, Wortelboer HM, Witkamp RF. Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions. CNS Neurol Disord Drug Targets 2013; 12: 23-33.
6. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 2017; 174: 1349-65.
7. Cristiano C, Pirozzi C, Coretti L, et al. Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms. Brain Behav Immun 2018; 74: 166-75.
8. Hill JD, Zuluaga-Ramirez V, Gajghate S, et al. Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation. Brain Behav Immun 2019; 76: 165-81.
9. Cordaro M, Cuzzocrea S, Crupi R. An update of palmitoylethanolamide and luteolin effects in preclinical and clinical studies of neuroinflammatory events. Antioxidants (Basel) 2020; 9: 216.
10. Féart C, Samieri C, Allès B, Barberger-Gateau P. Potential benefits of adherence to the Mediterranean diet on cognitive health. Proc Nutr Soc 2013; 72: 140-52.
11. Farooqui AA, Farooqui T. Effects of extra‐virgin olive oil in neurological disorders. In: Neuroprotective Effects of Phytochemicals in Neurological Disorders, Hoboken, NJ, USA, 2017.
12. Gallardo-Fernández M, Hornedo-Ortega R, Alonso-Bellido IM, et al. Hydroxytyrosol decreases LPS- and α-Synuclein-induced microglial activation in vitro. Antioxidants (Basel) 2019; 9: 36.
13. López de las Hazas MC, Godinho-Pereira J, Macia A, Almeida AF, Ventura R, Motilva MJ, Santos C. Brain uptake of hydroxytyrosol and its main circulating metabolites: Protective potential in neuronal cells. J Funct Foods 2018; 46: 110-7.
14. Rodríguez-Morató J, Xicota L, Fitó M, Farré M, Dierssen M, de la Torre R. Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases. Molecules 2015; 20: 4655-80.
15. Bigagli E, Cinci L, Paccosi S, Parenti A, D'Ambrosio M, Luceri C. Nutritionally relevant concentrations of resveratrol and hydroxytyrosol mitigate oxidative burst of human granulocytes and monocytes and the production of pro-inflammatory mediators in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol 2017; 43: 147-55.
16. Peng Y, Hou C, Yang Z, et al. Hydroxytyrosol mildly improve cognitive function independent of APP processing in APP/PS1 mice. Mol Nutr Food Res 2016; 60: 2331-42.
17. Fu P, Hu Q. 3, 4‑Dihydroxyphenylethanol alleviates early brain injury by modulating oxidative stress and Akt and nuclear factor‑κB pathways in a rat model of subarachnoid hemorrhage. Exp Ther Med 2016; 11: 1999-2004.
18. Mathew J, Paul J, Nandhu MS, Paulose CS. Bacopa monnieri and Bacoside-A for ameliorating epilepsy associated behavioral deficits. Fitoterapia 2010; 81: 315-22.
19. Sharma R, Chaturvedi C, Tewari P. Efficacy of Bacopa monniera in revitalizing intellectual functions in children. J Res Edu Ind Med 1987; 1: 12.
20. Negi K, Singh Y, Kushwaha K, et al. Clinical evaluation of memory enhancing properties of Memory Plus in children with attention deficit hyperactivity disorder. Indian J Psychiatry 2000; 42: 4.
21. Kishore K, Singh M. Effect of bacosides, alcoholic extract of Bacopa monniera Linn. (brahmi), on experimental amnesia in mice. Indian J Exp Biol 2005; 43: 640-5.
22. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med 2008; 14: 707-13.
23. Devishree R, Kumar S, Jain A. Short term effect of Bacopa monnieri on memory—A brief review. J Pharm Res 2017; 11: 1447-50.
24. Jeyasri R, Muthuramalingam P, Suba V, Ramesh M, Chen JT. Bacopa monnieri and their bioactive compounds inferred multi-target treatment strategy for neurological diseases: A cheminformatics and system pharmacology approach. Biomolecules 2020; 10: 536.
25. Komali E, Venkataramaiah C, Rajendra W. Antiepileptic potential of Bacopa monnieri in the rat brain during PTZ-induced epilepsy with reference to cholinergic system and ATPases. Journal of Traditional and Complementary Medicine 2020. https://doi.org/10.1016/j.jtcme.2020.02.011
26. Anbarasi K, Vani G, Balakrishna K, Devi CS. Effect of bacoside A on brain antioxidant status in cigarette smoke exposed rats. Life Sci 2006; 78: 1378-84.
27. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res 2013; 16: 313-26.
28. Lal S, Baraik B. Phytochemical and pharmacological profile of Bacopa monnieri-An ethnomedicinal plant. Int J Pharm Sci & Res 2019; 10: 1001-13.
29. Mathew J, Balakrishnan S, Antony S, Abraham PM, Paulose CS. Decreased GABA receptor in the cerebral cortex of epileptic rats: effect of Bacopa monnieri and Bacoside-A. J Biomed Sci 2012; 19: 25.
30. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014; 83: 253-60.
31. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol 2010; 127: 26-31.
32. Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive effect of nootropic drug brahmi (Bacopa monnieri) in Alzheimer's disease. Ann Neurosci 2017; 24: 111-22.